DiagnoCure, Inc. ( DiagnoCure) is a Canada-based life sciences company engaged in developing and commercializing high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. The Company is focused on the development and commercialization of molecular diagnostic tests for the detection and management of cancer. The Company also focuses on the development of genomic diagnostic tests for cancer. The Company�s product includes Analyte Specific Reagent. On February 15, 2012, the Company�s PROGENSA PCA3 test was approved by Food and Drug Administration (FDA). On August 1, 2012, Gen-Probe has become a wholly-owned subsidiary of Hologic Inc., licensee of the Company, which operates under the name Hologic Gen-Probe.